

**Metabolic Endocrine Education Foundation (MEEF)
638 Lindero Canyon Dr Suite # 380
Oak Park, CA 91377**

NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS, CA
PERMIT # 659

Register Online: www.wcir.org/registration

CME Symposium **22nd** IN ASSOCIATION WITH THE **WCIRDC**

EARN
CME
ABIM-MOC
CREDITS
1.0

Toward Reducing the Disease Burden of Heart Failure & Improve Patients Outcomes

Saturday, December 14, 2024
8:05 am – 9:05 am PST
Hilton Universal City Hotel
Los Angeles, California
BREAKFAST WILL BE SERVED

All content available ON-DEMAND for ONE YEAR following the meeting.

This is a CME Symposium Supported by an Educational Grant from **Bayer**
Free for all 22nd WCIRDC attendees. Register online: www.wcir.org/registration
This CME Symposium will be available and FREE for ONE year following the meeting.

Provided By:



Administered By:





TOWARD REDUCING THE DISEASE BURDEN OF HEART FAILURE & IMPROVE PATIENTS OUTCOMES

CHAIRS: **Mikhail N. Kosiborod, MD** • **Muthiah Vaduganathan, MD, MPH**

8:05 - 9:05 am **BREAKFAST CME SYMPOSIUM** Supported by **BAYER** **Sierra Ballroom CD**

8:05 am **Introduction**
Muthiah Vaduganathan, MD, MPH

8:10 am **Moonraker- Overview of the Investigators Led Research Program**
Mikhail N. Kosiborod, MD

8:25 am **FINEARTS-HF - Finerenone in Heart Failure with EF > 40%**
Orly Vardeny, PharmD, MS

8:40 am **FINE-HEART - Finerenone in Heart Failure and Chronic Kidney Disease Trials**
Muthiah Vaduganathan, MD, MPH

8:55 am **Panel Discussion: The Crystal Ball- ns MRA in the Guidelines**
Panel: Orly Vardeny, PharmD, MS • Muthiah Vaduganathan, MD, MPH
Moderator: Mikhail N. Kosiborod, MD

9:05 am **Adjourn**

Program Description

Heart Failure shares many etiologic pathways with obesity T2D, CVD, and CKD. Nearly 40% of patients with diabetes and Obesity have CKD heart failure and CVD. Currently HFpEF, for which effective treatments are limited, tracks the obesity epidemic occurs in > 50% of patients with heart failure. New treatment modalities are key to future improved outcome.

In this satellite symposium will learn of new studies identifying the important role of finerenone in the treatment for HF across a broad spectrum of patients and ejection fraction. Clinician will also understand the impact of Finerenone in patients with CKD & Heart Failure.

Learning Objectives

Upon completion of this CME symposium, participants should be able to:

Describe the goals and scope of MOONRAKER finerenone trials as a treatment for HF across a broad spectrum of patients

Know the results of FINEARTS-HF finerenone in symptomatic HF patients with an ejection fraction of $\geq 40\%$.

Understand the results of FINE-HEARTS establishing finerenone impact on patients with Heart Failure and Chronic Kidney Disease

Target Audience

This educational initiative is designed for cardiologists, nephrologists, endocrinologists, Diabetologists, primary care physicians, internists, and other healthcare professionals interested in the Epidemiology, pathophysiology of diabetes with CKD and the prevention of related morbidity and mortality.

FACULTY



Mikhail N. Kosiborod, MD
FACC, FAHA Chair

Vice President of Research
Endowed Chair in Cardiovascular Research
Saint Luke's Health System
Executive Director, Cardiometabolic Center Alliance
Co-Director the Haverly Cardiometabolic
Center of Excellence
Saint Luke's Mid-America Heart Institute
Professor of Medicine, University of Missouri
Kansas City, Missouri



Muthiah Vaduganathan, MD MPH, FACC, FHFA Chair

Cardiologist and Clinical Trialist
Brigham and Women's Hospital and
Harvard Medical School Co-director
Center for Cardiometabolic Implementation Science
Boston, Massachusetts



Orly Vardeny, PharmD, MS

Professor of Medicine University of Minnesota
Minneapolis, Minnesota

CME DINNER SYMPOSIUM

This CME symposium is FREE for 22nd WCIRDC attendees and will stay on-demand for ONE year following the meeting.

Learn more: WCIR.ORG/CMESymposium

To register for the entire 22nd WCIRDC meeting

Please visit: wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc., designated this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s).

Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact:

info@tmioa.com or 818 342 1889

This is a CME Program Supported by an Educational Grant from **Bayer**